EXCLUSIVE LICENSE AGREEMENT between Sorrento Therapeutics, Inc. and Icahn School of Medicine at Mount Sinai _______________________________________Exclusive License Agreement • May 5th, 2021 • Sorrento Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Exclusive License Agreement (this “Agreement”) is by and between Icahn School of Medicine at Mount Sinai, a New York not-for-profit education corporation, with a principal place of business at One Gustave L. Levy Place, New York, NY 10029 (“Mount Sinai”) and Sorrento Therapeutics, Inc., a Delaware corporation, with a principal place of business at 4955 Directors Place, San Diego, CA 92121 (referred to herein as “Sorrento” or “Licensee”). This Agreement will become effective on March 5, 2021, (the “Effective Date”).
Stock Appreciation Rights Award Agreement Award No. __________Award Agreement • May 5th, 2021 • Sorrento Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
You (the “Participant”) are hereby awarded the following stock appreciation rights (the “SARs”) with respect to Shares of Sorrento Therapeutics, Inc. (the “Company”), subject to the terms and conditions set forth in this Stock Appreciation Rights Award Agreement (as may be amended or restated from time to time, the “Award Agreement”) and in the Sorrento Therapeutics, Inc. 2021 Cash-Settled Stock Appreciation Rights Plan (as may be amended or restated from time to time, the “Plan”). The Plan is available upon request to the Company. You should carefully review these documents, and consult with your personal financial advisor, in order to fully understand the implications of this Award, including your tax alternatives or their consequences. This Award is conditioned on your execution of this Award Agreement within 21 days following the Grant Date designated in Section 1 below.
